Drugs Targeting the JAK/STAT Pathway for the Treatment of Immune-Mediated Inflammatory Skin Diseases: Protocol for a Scoping Review

May 2019 in “ BMJ Open ”

Francisco J. García, Pedro Jesús Gómez‐Arias, Jorge A. Hernández, Ana Montilla, Jesús Gay-Mimbrera, Macarena Aguilar-Luque, Isabel Viguera-Guerra, Antonio Vélez García‐Nieto, Beatriz Isla-Tejera, Juan Ruano

JAK/STAT pathway JAK/STAT inhibitors psoriasis atopic dermatitis alopecia areata vitiligo melanoma

Studysummary This review discusses the potential of drugs targeting the JAK/STAT pathway for dermatological diseases and outlines a protocol to assess existing evidence, reporting no new clinical results.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document described a protocol for a scoping review to evaluate the evidence on JAK/STAT pathway-targeting drugs for treating immune-mediated inflammatory skin diseases, including alopecia areata. At the time, no JAK/STAT inhibitors were approved for skin disease treatment, despite their potential. The review aimed to systematically gather and summarize existing research, identify knowledge gaps, and formulate new research questions regarding these drugs' indications, mechanisms, efficacy, and safety. The study highlighted the importance of evidence-based medicine and aimed to improve decision-making in dermatology. The results were intended to provide insights into the use of JAK/STAT inhibitors and guide future research.

View this study on bmjopen.bmj.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Janus Kinase Inhibitors in Dermatology: A Systematic Review

116 citations , February 2017 in “Journal of the American Academy of Dermatology”

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature

40 citations , December 2016 in “Journal of Dermatological Treatment”

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.